Xabans—direct factor Xa inhibitors (Rivaroxaban, Apixaban, and Edoxaban) are orally administrated non‐vitamin K‐dependent direct factor Xa inhibitors (NOACs)1, 2, 3 with few strong drug interactions that are approved for the prevention of embolic events in patients with atrial fibrillation (AF). Here, F10 is linked to atrial fibrillation.